Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants

EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection

(2015)   JOURNAL OF HEPATOLOGY

Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis

(2012) Roeland Zoutendijk et al.   GUT

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

(2012) Yun-Fan Liaw et al.   Hepatology International

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B

(2010) Ting-Tsung Chang et al.   HEPATOLOGY

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B

(2010) Ting-Tsung Chang et al.   HEPATOLOGY

Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review

(2010) George V. Papatheodoridis et al.   JOURNAL OF HEPATOLOGY

HEPATOLOGY: A home for hepatocellular cancer publications

(2009) Gregory J. Gores   HEPATOLOGY

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

(2009) Daniel J. Tenney et al.   HEPATOLOGY

Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma

(2008) J. J. Y. SUNG et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir

(2008) Nancy Leung et al.   HEPATOLOGY